(CME) CME - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US12572Q1058
Stock: Futures, Options, Clearing, Market-Data
Total Rating 41
Risk 52
Buy Signal -0.13
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.90% |
| Yield on Cost 5y | 3.15% |
| Yield CAGR 5y | -7.57% |
| Payout Consistency | 93.5% |
| Payout Ratio | 59.2% |
| Risk 5d forecast | |
|---|---|
| Volatility | 17.8% |
| Relative Tail Risk | 3.12% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.11 |
| Alpha | 24.09 |
| Character TTM | |
|---|---|
| Beta | -0.062 |
| Beta Downside | -0.018 |
| Drawdowns 3y | |
|---|---|
| Max DD | 11.65% |
| CAGR/Max DD | 1.95 |
Description: CME CME January 27, 2026
CME Group Inc. (NASDAQ:CME) operates global futures and options exchanges covering interest rates, equity indexes, FX, agricultural commodities, energy, metals, and fixed-income products. It also provides clearing, settlement, risk-mitigation, and market-data services to a broad client base that includes professional traders, banks, corporations, governments and central banks.
Recent metrics show CME’s revenue reached $5.62 billion in FY 2024, up 4 % YoY, driven by a 12 % increase in clearing volume amid heightened interest-rate volatility and a 9 % rise in market-data subscriptions (CME Q4 2024 earnings release). The firm’s net income rose to $2.03 billion, reflecting strong margin-call collections and expanding swap-clearing business, while its market-share in U.S. interest-rate futures remains above 60 %.
For a deeper quantitative view of CME’s valuation metrics, you might explore the analyst tools on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: 3.75b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.45 > 1.0 |
| NWC/Revenue: 50.23% < 20% (prev 38.40%; Δ 11.83% < -1%) |
| CFO/TA 0.02 > 3% & CFO 4.16b > Net Income 3.75b |
| Net Debt (968.0m) to EBITDA (5.35b): 0.18 < 3 |
| Current Ratio: 1.02 > 1.5 & < 3 |
| Outstanding Shares: last quarter (360.3m) vs 12m ago 0.09% < -2% |
| Gross Margin: 86.14% > 18% (prev 0.86%; Δ 8528 % > 0.5%) |
| Asset Turnover: 3.94% > 50% (prev 4.39%; Δ -0.45% > 0%) |
| Interest Coverage Ratio: 29.45 > 6 (EBITDA TTM 5.35b / Interest Expense TTM 170.4m) |
Altman Z'' 0.46
| A: 0.02 (Total Current Assets 152.80b - Total Current Liabilities 149.59b) / Total Assets 187.14b |
| B: 0.03 (Retained Earnings 5.71b / Total Assets 187.14b) |
| C: 0.03 (EBIT TTM 5.02b / Avg Total Assets 162.47b) |
| D: 0.04 (Book Value of Equity 5.75b / Total Liabilities 158.95b) |
| Altman-Z'' Score: 0.46 = B |
Beneish M -3.18
| DSRI: 0.97 (Receivables 642.9m/629.4m, Revenue 6.40b/6.04b) |
| GMI: 1.00 (GM 86.14% / 86.06%) |
| AQI: 0.73 (AQ_t 0.18 / AQ_t-1 0.25) |
| SGI: 1.06 (Revenue 6.40b / 6.04b) |
| TATA: -0.00 (NI 3.75b - CFO 4.16b) / TA 187.14b) |
| Beneish M-Score: -3.18 (Cap -4..+1) = AA |
What is the price of CME shares?
As of February 07, 2026, the stock is trading at USD 302.27 with a total of 2,927,380 shares traded.
Over the past week, the price has changed by +4.57%, over one month by +12.31%, over three months by +11.88% and over the past year by +26.03%.
Over the past week, the price has changed by +4.57%, over one month by +12.31%, over three months by +11.88% and over the past year by +26.03%.
Is CME a buy, sell or hold?
CME has received a consensus analysts rating of 3.39.
Therefor, it is recommend to hold CME.
- StrongBuy: 4
- Buy: 3
- Hold: 7
- Sell: 4
- StrongSell: 0
What are the forecasts/targets for the CME price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 289.7 | -4.2% |
| Analysts Target Price | 289.7 | -4.2% |
| ValueRay Target Price | 356.5 | 17.9% |
CME Fundamental Data Overview February 04, 2026
P/E Trailing = 28.1754
P/E Forward = 24.5098
P/S = 16.3715
P/B = 3.6864
P/EG = 5.4003
Revenue TTM = 6.40b USD
EBIT TTM = 5.02b USD
EBITDA TTM = 5.35b USD
Long Term Debt = 3.42b USD (from longTermDebt, last quarter)
Short Term Debt = 749.8m USD (from shortTermDebt, last fiscal year)
Debt = 3.42b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 968.0m USD (from netDebt column, last quarter)
Enterprise Value = 105.38b USD (104.54b + Debt 3.42b - CCE 2.58b)
Interest Coverage Ratio = 29.45 (Ebit TTM 5.02b / Interest Expense TTM 170.4m)
EV/FCF = 25.80x (Enterprise Value 105.38b / FCF TTM 4.08b)
FCF Yield = 3.88% (FCF TTM 4.08b / Enterprise Value 105.38b)
FCF Margin = 63.84% (FCF TTM 4.08b / Revenue TTM 6.40b)
Net Margin = 58.64% (Net Income TTM 3.75b / Revenue TTM 6.40b)
Gross Margin = 86.14% ((Revenue TTM 6.40b - Cost of Revenue TTM 886.7m) / Revenue TTM)
Gross Margin QoQ = 84.55% (prev 86.90%)
Tobins Q-Ratio = 0.56 (Enterprise Value 105.38b / Total Assets 187.14b)
Interest Expense / Debt = 1.29% (Interest Expense 44.0m / Debt 3.42b)
Taxrate = 22.85% (269.0m / 1.18b)
NOPAT = 3.87b (EBIT 5.02b * (1 - 22.85%))
Current Ratio = 1.02 (Total Current Assets 152.80b / Total Current Liabilities 149.59b)
Debt / Equity = 0.12 (Debt 3.42b / totalStockholderEquity, last quarter 28.19b)
Debt / EBITDA = 0.18 (Net Debt 968.0m / EBITDA 5.35b)
Debt / FCF = 0.24 (Net Debt 968.0m / FCF TTM 4.08b)
Total Stockholder Equity = 27.36b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.31% (Net Income 3.75b / Total Assets 187.14b)
RoE = 13.71% (Net Income TTM 3.75b / Total Stockholder Equity 27.36b)
RoCE = 16.30% (EBIT 5.02b / Capital Employed (Equity 27.36b + L.T.Debt 3.42b))
RoIC = 12.58% (NOPAT 3.87b / Invested Capital 30.78b)
WACC = 5.54% (E(104.54b)/V(107.96b) * Re(5.69%) + D(3.42b)/V(107.96b) * Rd(1.29%) * (1-Tc(0.23)))
Discount Rate = 5.69% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.09%
[DCF Debug] Terminal Value 87.38% ; FCFF base≈3.90b ; Y1≈4.37b ; Y5≈5.79b
Fair Price DCF = 472.0 (EV 170.67b - Net Debt 968.0m = Equity 169.70b / Shares 359.5m; r=5.90% [WACC]; 5y FCF grow 13.81% → 2.90% )
EPS Correlation: -16.98 | EPS CAGR: -45.61% | SUE: -4.0 | # QB: 0
Revenue Correlation: 89.99 | Revenue CAGR: 8.12% | SUE: 0.54 | # QB: 0
EPS next Quarter (2026-03-31): EPS=2.95 | Chg30d=+0.041 | Revisions Net=+4 | Analysts=12
EPS next Year (2026-12-31): EPS=11.72 | Chg30d=+0.071 | Revisions Net=+1 | Growth EPS=+4.8% | Growth Revenue=+4.8%
P/E Forward = 24.5098
P/S = 16.3715
P/B = 3.6864
P/EG = 5.4003
Revenue TTM = 6.40b USD
EBIT TTM = 5.02b USD
EBITDA TTM = 5.35b USD
Long Term Debt = 3.42b USD (from longTermDebt, last quarter)
Short Term Debt = 749.8m USD (from shortTermDebt, last fiscal year)
Debt = 3.42b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 968.0m USD (from netDebt column, last quarter)
Enterprise Value = 105.38b USD (104.54b + Debt 3.42b - CCE 2.58b)
Interest Coverage Ratio = 29.45 (Ebit TTM 5.02b / Interest Expense TTM 170.4m)
EV/FCF = 25.80x (Enterprise Value 105.38b / FCF TTM 4.08b)
FCF Yield = 3.88% (FCF TTM 4.08b / Enterprise Value 105.38b)
FCF Margin = 63.84% (FCF TTM 4.08b / Revenue TTM 6.40b)
Net Margin = 58.64% (Net Income TTM 3.75b / Revenue TTM 6.40b)
Gross Margin = 86.14% ((Revenue TTM 6.40b - Cost of Revenue TTM 886.7m) / Revenue TTM)
Gross Margin QoQ = 84.55% (prev 86.90%)
Tobins Q-Ratio = 0.56 (Enterprise Value 105.38b / Total Assets 187.14b)
Interest Expense / Debt = 1.29% (Interest Expense 44.0m / Debt 3.42b)
Taxrate = 22.85% (269.0m / 1.18b)
NOPAT = 3.87b (EBIT 5.02b * (1 - 22.85%))
Current Ratio = 1.02 (Total Current Assets 152.80b / Total Current Liabilities 149.59b)
Debt / Equity = 0.12 (Debt 3.42b / totalStockholderEquity, last quarter 28.19b)
Debt / EBITDA = 0.18 (Net Debt 968.0m / EBITDA 5.35b)
Debt / FCF = 0.24 (Net Debt 968.0m / FCF TTM 4.08b)
Total Stockholder Equity = 27.36b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.31% (Net Income 3.75b / Total Assets 187.14b)
RoE = 13.71% (Net Income TTM 3.75b / Total Stockholder Equity 27.36b)
RoCE = 16.30% (EBIT 5.02b / Capital Employed (Equity 27.36b + L.T.Debt 3.42b))
RoIC = 12.58% (NOPAT 3.87b / Invested Capital 30.78b)
WACC = 5.54% (E(104.54b)/V(107.96b) * Re(5.69%) + D(3.42b)/V(107.96b) * Rd(1.29%) * (1-Tc(0.23)))
Discount Rate = 5.69% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.09%
[DCF Debug] Terminal Value 87.38% ; FCFF base≈3.90b ; Y1≈4.37b ; Y5≈5.79b
Fair Price DCF = 472.0 (EV 170.67b - Net Debt 968.0m = Equity 169.70b / Shares 359.5m; r=5.90% [WACC]; 5y FCF grow 13.81% → 2.90% )
EPS Correlation: -16.98 | EPS CAGR: -45.61% | SUE: -4.0 | # QB: 0
Revenue Correlation: 89.99 | Revenue CAGR: 8.12% | SUE: 0.54 | # QB: 0
EPS next Quarter (2026-03-31): EPS=2.95 | Chg30d=+0.041 | Revisions Net=+4 | Analysts=12
EPS next Year (2026-12-31): EPS=11.72 | Chg30d=+0.071 | Revisions Net=+1 | Growth EPS=+4.8% | Growth Revenue=+4.8%